PHASE 1 TRIAL OF THE LSD1 INHIBITOR SECLIDEMSTAT (SP-2577) WITH AND WITHOUT TOPOTECAN AND CYCLOPHOSPHAMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY EWING SARCOMA AND SELECT SARCOMAS
This is an open label, phase I trial to evaluate the safety of an orally administered targeted agent, seclidemstat (LSD1 inhibitor) in combination with cyclophosphamide and topotecan, in patients with relapsed or refractory Ewing sarcoma who have received at least one line of prior treatment for Ewing sarcoma. The trial also enrolls both myxoid liposarcoma and Ewing-related sarcomas which share a similar translocation gene as Ewing sarcoma, who have received at least two prior lines of treatment for their sarcoma. The myxoid liposarcoma and translocated sarcoma patients will be enrolled to single-agent seclidemstat. This trial has completed the dose escalation phase of the trial and is now in dose expansion. The primary objective is safety and tolerability of seclidemstat, alone, and in combination with standard chemotherapy.
ClinicalTrials.gov: https://clinicaltrials.gov/ct2/show/NCT03600649?term=salarius&draw=2&rank=2
Sponsor Website: http://salariuspharma.com/